Biosimilar anti-TNF-α medicines have been shown to offer consistent outcomes in terms of clinical efficacy and safety in IBD [48,49], while also permitting substantial cost savings and potential reinvestment. The gene discussed is TNF; the disease is inflammatory bowel disease.